Theravance Biopharma预计重组行动将产生500万至700万美元一次性现金遣散成本

美股速递
May 07

生物制药公司Theravance Biopharma宣布,因实施重组计划,预计将承担约500万至700万美元的一次性现金遣散费用。此次重组行动旨在优化公司运营结构,相关成本主要涉及员工离职补偿。该笔费用将作为特殊项目计入财务报表,不影响公司核心业务的持续经营能力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10